Support teaching, research, and patient care.
Christina Curtis, PhD, MSc is the RZ Cao Professor of Medicine, Genetics and Biomedical Data Science at Stanford University where she also serves as the Director of Artificial Intelligence and Cancer Genomics and of Breast Cancer Translational Research. Dr. Curtis’s laboratory leverages computational modeling, high-throughput molecular profiling and experimentation to develop new ways to prevent, diagnose and treat cancer. Her research has redefined the molecular map of breast cancer and led to new paradigms in understanding the origins of human cancers, as well as how they evolve and metastasize. Dr. Curtis has been the recipient of numerous awards, including the National Institutes of Health (NIH) Director's Pioneer Award (2018) and the American Association for Cancer Research (AACR) Award for Outstanding Achievement in Basic Science (2022). She is a Kavli Fellow of the National Academy of Sciences, a Susan G. Komen Scholar, and a Chan Zuckerberg Biohub Investigator. Dr. Curtis is a member of Board of Reviewing Editors at Science, the AACR Board of Directors, and is a scientific advisor to biotech/biopharma.
Breast cancer therapy, metastasis
National Cancer Institute
Bioinformatics /Translational cancer research/clinical trials
Molecular characterization of cancer and pre-cancer
We are interested in elucidating tumor evolutionary dynamics, novel therapeutic targets, and the genotype to phenotype map in cancer. A unifying theme of our research is to exploit ‘omic’ data derived from clinically annotated samples in robust computational frameworks coupled with iterative experimental validation in order to advance our understanding of cancer systems biology. In particular, we employ advanced genomic techniques, computational and mathematical modeling, and powerful model systems in order to:1.) Model the evolutionary dynamics of tumor progression and therapeutic resistance and metastasis2) Elucidate disease etiology and novel molecular targets through integrative analyses of high-throughput omic data3) Develop techniques for the systems-level interpretation of genotype-phenotype associations in cancerOur research is funded by the NIH/NCI, NHGRI, Department of Defense, Breast Cancer Research Foundation, American Association for Cancer Research, Susan G. Komen Foundation, Emerson Collective and V Foundation for Cancer Research.
Umbrella Trial Testing Integrative Subtype-Targeted Therapeutics in HR+ /HER2-Negative Breast Cancer
The purpose of this study is to learn if adding a new drug that is targeted at a specific
genetic change found in some breast tumors pre-operatively will slow the growth of the tumor
more than standard anti-hormone therapy used to treat this type of breast cancer. Different
therapies are being tested based on the specific gene changes in the tumor. Not every tumor
will have a gene change that is being studied.
View full details
Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer
The purpose of the study is identify the dose(s) of infigratinib to use in combination with
tamoxifen to treat patients with a particular type of advanced breast cancer (hormone
receptor-positive, HER2-negative, FGFR-altered breast cancer)
Stanford is currently not accepting patients for this trial.
For more information, please contact Lisa Kody, 650-498-8583.